Focus: ResMed is a $4.2B public medical device company headquartered in San Diego specializing in cloud-connected devices and software for respiratory, sleep, and cardiopulmonary conditions. The company dominates the positive airway pressure (PAP) and non-invasive ventilation markets with a global installed base across home and acute care settings.
Profile data last refreshed 6h ago · AI intelligence enriched 2mo ago
No open roles listed right now. Follow ResMed to get notified when they start hiring — the background below is worth knowing for when they do.
Flagship market-leading CPAP device with cloud connectivity; represents core revenue driver in OSA market.
Help build intelligence for ResMed
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from ResMed's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Advanced ventilation therapy device addressing higher-acuity cardiopulmonary indications; Phase 4 study in heart failure indicates continued clinical validation.
Established COPD accessory product with recurring revenue model via device supplies and consumables.
Watch ResMed’s GLP-1 Fear Fade as Data Tells a Different Story - Kalkine Media
Watch ResMed’s GLP-1 Fear Fade as Data Tells a Different Story Kalkine Media
ResMed Shares Slide Into The Weekend: What Is The Latest? - thebull.com.au
ResMed Shares Slide Into The Weekend: What Is The Latest? thebull.com.au
ResMed snaps up Noctrix Health in $340M sleep tech deal - Fierce Biotech
ResMed snaps up Noctrix Health in $340M sleep tech deal Fierce Biotech
ResMed completes $340m Noctrix Health acquisition - Medical Device Network
ResMed completes $340m Noctrix Health acquisition Medical Device Network
Resmed tackles restless legs syndrome with Noctrix Health takeover - Mugglehead Investment Magazine
Resmed tackles restless legs syndrome with Noctrix Health takeover Mugglehead Investment Magazine
Resmed completes $340M acquisition of Noctrix Health - MassDevice
Resmed completes $340M acquisition of Noctrix Health MassDevice
Showing 6 of 10 news items
No open positions listed yet. Check their careers page directly.
Based on last 4 crawl cycles
Source: USCIS H-1B Employer Data Hub
Recent peer-reviewed publications with author affiliations at this company
Showing 5 of 10 publications
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo